Information About

D-dimer





INDICATIONS

D-dimer testing is of clinical use when there is a suspicion of Deep Venous Thrombosis (DVT) or Pulmonary Embolism (PE). In patients suspected of Disseminated Intravascular Coagulation (DIC), D-dimers may aid in the diagnosis.

For DVT and PE, there are various scoring systems that are used to determine the ''a priori'' clinical probability of these diseases; the best-known were introduced by Wells ''et al'' (2003).
  • In a very high score, a D-dimer will make little difference, and Anticoagulant therapy will be initiated regardless of test results.

  • In a moderate or low score:

  • --- A negative D-dimer test will virtually rule out thromboembolism.

  • --- If the D-dimer reads high, then further testing ( Ultrasound of the leg veins or lung Scintigraphy or CT Scanning ) is required to confirm the presence of Thrombus before Anticoagulant therapy can be continued.



REFERENCE RANGE

Most sampling kits have 0-300 Ng / Ml as normal range. Values exceeding 250, 300 or 500 ng/ml (different for various kits) are considered positive.


TYPES OF ASSAYS

  • ELISA (e.g. SimpliRED®, Vidas®)

  • Latex turbidimetric assay (automated immunoassay, e.g. Roche Tina-quant®, MDA D-dimer®)

  • Enhanced microlatex

  • Latex-enhanced photometric



PRINCIPLES

Fibrin Degradation Product s (FDPs) are formed whenever Fibrin is Broken Down by Enzyme s (e.g. Plasmin ). Determining FDPs is not considered useful, as this does not indicate whether the fibrin is part of a blood clot (or being generated as part of Inflammation ).

D-dimers are unique in that they are the breakdown products of a fibrin mesh that has been stabilised by Factor XIII . This factor crosslinks the E-element to ''two'' D-elements. This is the final step in the generation of a thrombus.

Plasmin is a natural Fibrinolytic enzyme that organises clots and breaks down the fibrin mesh. It cannot, however, break down the bonds between one E and two D units. The protein fragment thus left over is a D-dimer.

D-dimer assays rely on Monoclonal Antibodies to bind to this specific protein fragment. The first patented MoAb of the kind was ''D Dimer-3B6/22'', although others have been developed.


SENSITIVITY AND SPECIFICITY

Various kits have a 93-95% sensitivity and about 50% specificity in the diagnosis of thrombotic disease (Schrecengost ''et al'' 2003).
  • disease, high Rheumatoid Factor , Inflammation , Malignancy , Trauma , Pregnancy , recent Surgery as well as advanced age

  • False Negative readings can occur if the sample is taken either too early after thrombus formation or if testing is delayed for several days. Additionally, the presence of anti-coagulation can render the test negative because it prevents thrombus extension.



HISTORY

D-dimer testing was originally developed in the diagnosis of disseminated intravascular coagulation. In the 1990s , they turned out to be useful in thromboembolic disorders.


REFERENCES

  • Schrecengost JE, LeGallo RD, Boyd JC, Moons KG, Gonias SL, Rose CE Jr, Bruns DE. ''Comparison of diagnostic accuracies in outpatients and hospitalized patients of D-dimer testing for the evaluation of suspected pulmonary embolism.'' Clin Chem 2003;49:1483-90. PMID 12928229.

  • Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, Kovacs G, Mitchell M, Lewandowski B, Kovacs MJ. ''Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis.'' N Engl J Med 2003;349:1227-35. PMID 14507948.



EXTERNAL LINK